Equillium, Inc. (EQ)
After hours:
| Previous close | 3.1400 |
| Open | 3.0100 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1300 |
| Day's range | 2.7000 - 3.0400 |
| 52-week range | 1.6600 - 7.1200 |
| Volume | |
| Avg. volume | 29,398 |
| Market cap | 107.866M |
| Beta (5Y monthly) | 1.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2540 |
| Earnings date | 08 Nov 2022 - 14 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.17 |
- Simply Wall St.
What Kind Of Shareholders Hold The Majority In Equillium, Inc.'s (NASDAQ:EQ) Shares?
A look at the shareholders of Equillium, Inc. ( NASDAQ:EQ ) can tell us which group is most powerful. Insiders often...
- Business Wire
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates
LA JOLLA, Calif., August 15, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2022 and provided an update on its clinical development programs.
- Business Wire
Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit
LA JOLLA, Calif., July 28, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a presentation at the 3rd Annual Cytokine-Based Drug Development Summit. The presentation highlights Equillium’s multi-cytokine inhibitor technology and platform, and applications of cytokine technology beyond oncology. Data on the platform, including the l
